SCPS (Scopus BioPharma) Operating Income: $-9.34 Mil (TTM As of Jun. 2023)

What is Scopus BioPharma Operating Income?

Scopus BioPharma SCPS Operating Income is $-9.34 Mil as of Jun. 2023.

Scopus BioPharma's Operating Income for the three months ended in Jun. 2023 was $-2.93 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Jun. 2023 was $-9.34 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. Scopus BioPharma's Operating Income for the three months ended in Jun. 2023 was $-2.93 Mil. Scopus BioPharma's Revenue for the three months ended in Jun. 2023 was $0.00 Mil. Therefore, Scopus BioPharma's Operating Margin % for the quarter that ended in Jun. 2023 was %.

Scopus BioPharma's 5-Year average Growth Rate for Operating Margin % was 0.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Scopus BioPharma's annualized ROC % for the quarter that ended in Jun. 2023 was -9,082.17%. Scopus BioPharma's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2023 was -585,800.00%.

Scopus BioPharma (OTCPK:SCPS) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Scopus BioPharma's annualized ROC % for the quarter that ended in Jun. 2023 is calculated as:

	ROC % (Q: Jun. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Mar. 2023 )	+	Invested Capital (Q: Jun. 2023 ))	/ count )
=	-11.716 * ( 1 - 0% )	/	( (0.163	+	0.094999999999999)	/ 2 )
=	-11.716	/	0.129
=	-9,082.17 %

where

	Invested Capital		(Q: Mar. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	1.603	-	9.152	-	( 1.401	-	max(0, 9.313	-	1.601	+	1.401	))
=	0.163

	Invested Capital		(Q: Jun. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0.498	-	10.909	-	( 0.362	-	max(0, 11.002	-	0.496	+	0.362	))
=	0.094999999999999

Note: The Operating Income data used here is four times the quarterly (Jun. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Scopus BioPharma's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Jun. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Mar. 2023		Q: Jun. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-11.716	/	( ( (0.002 + max(-9.113, 0))	+	(0.002 + max(-10.868, 0)) )	/	2 )
=	-11.716	/	( ( 0.002	+	0.002 )	/	2 )
=	-11.716	/	0.002
=	-585,800.00 %

where Working Capital is:

	Working Capital		(Q: Mar. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.2)	-	(9.152	+	0	+	0.161)
=	-9.113

	Working Capital		(Q: Jun. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.134)	-	(10.909	+	0	+	0.093)
=	-10.868

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Jun. 2023) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Scopus BioPharma's Operating Margin % for the quarter that ended in Jun. 2023 is calculated as:

Operating Margin %	=	Operating Income (Q: Jun. 2023 )	/	Revenue (Q: Jun. 2023 )
	=	-2.929	/	0
	=	%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.

Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.

Scopus BioPharma Operating Income Related Terms

Scopus BioPharma Operating Income Historical Data

* Premium members only.

The historical data trend for Scopus BioPharma's Operating Income can be seen below:

Scopus BioPharma Operating Income Chart

Scopus BioPharma Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Operating Income

Get a 7-Day Free Trial

-0.69

-2.69

-10.16

-27.64

-11.72

Scopus BioPharma Quarterly Data
	Jun18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Operating Income	Get a 7-Day Free Trial															-3.32	-1.90	-1.84	-2.68	-2.93

Scopus BioPharma Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-9.34 Mil.

Frequently Asked Questions Learn more about Operating Income →

What does a Operating Income of $-9.34 Mil mean?

Scopus BioPharma (SCPS) has a Operating Income of $-9.34 Mil as of Jun. 2023. Operating Income equals sales less all operating expenses. It is linked to EBIT. View historical data on Scopus BioPharma and its competitors.

Is Scopus BioPharma's Operating Income too high?

Scopus BioPharma's current Operating Income is $-9.34 Mil.

How does Scopus BioPharma's Operating Income compare to AMPE and DRMA?

Scopus BioPharma's Operating Income of $-9.34 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Operating Income for a Biotechnology company?

A good Operating Income depends on the Biotechnology industry context. However, Operating Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Operating Income mean?

A high Operating Income can signal that a stock is expensive relative to its fundamentals. Operating Income equals sales less all operating expenses. It is linked to EBIT. View historical data on Scopus BioPharma and its competitors. Scopus BioPharma's current Operating Income is $-9.34 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Scopus BioPharma stock overvalued right now?

Scopus BioPharma (SCPS) has a current Operating Income of $-9.34 Mil. The current Operating Income is $-9.34 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Operating Income calculated?

Operating Income is calculated from a company's financial statements. For Scopus BioPharma (SCPS), the current Operating Income is $-9.34 Mil as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Scopus BioPharma Business Description

Industry Healthcare Biotechnology

Comparable Companies AMPE DRMA SPRC GSTC INM BXRX NBRVF SONN PKBO ADTX OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX

Address 420 Lexington Avenue, Suite 300, New York, NY, USA, 10170

Website https://www.scopusbiopharma.com

Scopus BioPharma Inc a biotechnology company focused on developing therapeutics targeting the endocannabinoid system. The endocannabinoid system is comprised of chemical compounds, or cannabinoids, that interact with cannabinoid receptors which are located throughout the body. Its product candidate comprises CO-sTiRNA, which is a STAT3 inhibitor gene therapy and MRI-1867.